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ABSTRACT
MECHANISM OF ANTI-VIRULENCE COMPOUND 187R INHIBITING
PSEUDOMONAS AERUGINOSA TYPE III SECRETION SYSTEM
by
Liwei Fang
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Ching-Hong Yang, Ph.D.

Antibiotics have been widely used for treating bacterial infectious diseases. However, the
rapidly emerging of antibiotic resistance has dramatically decreased the efficacy of antibiotics
and poses a serious worldwide crisis. In addition, the cell components serving as antibiotics’
targets are conserved in many different bacterial species, as a result, antibiotic treatments
disrupt the host microbiota and negatively influence the hosts health condition. Therefore, new
alternative strategies for fighting infectious diseases without causing antibiotic resistance and
disturbing the host microbiota are needed. Type 3 secretion system (T3SS) is a highly
conserved virulence factor presents in many different Gram-negative pathogens. It is required
for pathogens such as P. aeruginosa, surviving and initiating infection in their hosts. Therefore,
targeting the T3SS is a promising alternative strategy for developing new antimicrobial
therapies without disrupting the hosts’ microbial community. Here, we identified a potent T3SS
inhibitor, designated 187R, which strongly inhibits the expression of P. aeruginosa T3SS. Our
data suggests that 187R inhibits T3SS expression through reducing the T3SS master regulator
ExsA at the post-translational level. The impact of this anti-virulence compound on the hosts’
microbial community was also tested using Arabidopsis thaliana phyllosphere as a model. We
demonstrates that compared to the traditional antibiotics, our T3SS inhibitor 187R can preserve
the microbial community better than antibiotics.
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Chapter 1 : Introduction
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Pseudomonas aeruginosa
Pseudomonas aeruginosa is a facultative anaerobic, Gram negative, rod-shaped bacterium
which belongs to the family of gammaproteobacteria. It is able to survive under a wide range
of temperatures from 4°C to 42°C. The genome analysis of the PAO1 strain shows that many
genes function as substrate uptake or catalysis, which enable the bacteria to use various
substances as nutrients (1). The bacterium is also able to survive under anaerobic conditions
either by utilizing nitrate or nitrite as alternative external electron acceptors or by fermenting
arginine or pyruvate as its energy source (2). All these features allow P. aeruginosa to adapt
to different types of environments such as soil and water.
P. aeruginosa is an opportunistic pathogen causing acute and chronic infections in
immunocompromised patients (3). It is a major cause of nosocomial infections which affects 2
millions patients per year. Cystic fibrosis (CF) patients are the group most vulnerable to P.
aeruginosa. The pathogen is the leading cause of morbidity and mortality in CF patients. In
healthy individuals, the infection caused by P. aeruginosa tends to occur after skin or eye
damage (4). Moreover, the bacteria is able to form robust biofilm on the surface of medical
devices which causes biofilm-mediated infections such as ventilator-associated pneumonia
and catherter-associated urinary tract infection (5). The biofilm is hard to remove from the
medical devices and triggers chronic infections. The only solution for stopping the biofilmassociated infection is to replace the medical devices (6). Hospital-acquired infections caused
by P. aeruginosa have become a serious concern as the pathogen is resistant to different types
of antibiotics. As a result, the bacteria is hard to eradicate from the patients and causes serious
health issues (7).
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Pathogenesis of P. aeruginosa
P. aeruginosa has a variety of virulence factors that lead to successful infections. Previous
research showed that P. aeruginosa isolates from patients with acute infections are generally
motile and capable of secreting toxins that cause host cell damage (8). These studies indicate
that motility and toxin secretion are important for P. aeruginosa acute infections. Flagellar and
type IV pili are bacterial cell surface virulence factors that are responsible for twitching,
swimming and swarming motilities (9). These virulence factors enable P. aeruginosa to search
for optimal niches. Type IV pili and flagella also mediate the adhesion to the airway epithelia
cells, which is the first step towards colonization and disease initiation (10).
The secretion systems are also crucial for the virulence of P. aeruginosa. This pathogen
possesses five different classes of secretion systems, all of which enable the pathogen to secrete
different types of toxins into the environment or into host cells (11). In P. aeruginosa, two
Type 1 secretion systems (T1SS) named T1SS (Apr) and T1SS (Has) have been discovered
(12). The first T1SS, T1SS (Apr), secretes alkaline protease protein which interferes with
complement activation thereby preventing phagocytosis and the death of P. aeruginosa (13).
The second T1SS, T1SS (Has) secretes the heme acquisition protein which is crucial for iron
acquisition from the environment (14). Type 2 secretion systems (T2SS) are important for the
virulence of P. aeruginosa as the system secretes toxins such as elastase and exotoxin A that
are believed to cause extensive tissue damage during the infection. It has also been proven that
the T2SS is highly similar to type 4 pilus assembly system (T4PS) and can assemble type 2
pseudopilus. The presence of type 2 pseudopilus on P. aeruginosa increases the bacteria’s
adhesive ability and elevates the virulence of the bacteria (15). Type 3 secretion system is a
needle like structure that translocates the effector proteins (toxins) from bacteria cytoplasm
into the host cell. The effector proteins cause host cell death and tissue damage (16). The Type
5 secretion system not only secrets toxins such as patatin-like proteins (PLPs) (17), but is also
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critical for the cell to cell adhesion and biofilm formation (11). The type 6 secretion system
(T6SS) delivers the toxin into other bacteria cells. T6SS of P. aeruginosa also helps it compete
with the other bacteria and survive in the microbial community (18).

T3SS is a primary acute virulence factor
Type 3 secretion system (T3SS) is considered the primary acute virulence factor for P.
aeruginosa (19). Previous research showed that in both chronic and acute infection models, the
presence of fully functional T3SS is associated with increased mortality rates (20). The
increased severity of disease is not only due to tissue damage caused by the T3SS effector
protein, but also by the cytotoxicity towards the immune cells such as the macrophages (21).
Additionally, P. aeruginosa T3SS is involved in killing amoebae. Since predation by
phagotrophic protists is the major cause of bacterial populations decreasing in many
ecosystems, a fully functional T3SS is required for the bacteria’s higher survival rate in the
environment (22).

Structure of T3SS
T3SS is a needle-like structure that directly translocates the effector proteins (toxins) from
the bacterial cytoplasm into the host cells (23). This multi-protein complex apparatus is
composed of a needle-like injectisome and a basal body (Fig. 1.1A). The needle-like structure
anchors on the basal body, which extends through the inner membrane, peptidoglycan layer
and outer membrane. The basal body and the needle structure is built up under the nonsecreting condition. Once the bacteria make contact with the host cell, PopB, PopD and PcrV
are secreted directly by the T3SS. These three proteins forms translocation pores on the host
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cell plasma membrane which allows effector proteins (toxins) transferred directly into the host
cell through the translocation apparatus into the host cytosol (24).

Effector proteins of P. aeruginosa T3SS
In P. aeruginosa, four effector proteins named ExoS, ExoT, ExoY and ExoU have been
discovered. These four effectors normally are not all present in one single strain; either ExoS
or ExoU are absent in different strains (25). Studies of the T3SS effector proteins showed that
these four effectors have different enzyme activity. As the most potent T3SS effector, ExoU
showed strong phospholipase/lysophospholipase activity and resulted cell lysis through
destroying host cell membrane (25). Two other effector proteins ExoS and ExoT share highly
similar amino acids sequences. Both are bifunctional proteins with an GTPase-activating Nterminal domain and adenosine diphosphate ribosyltransferase (ADPRT) C-terminal domain.
After injection, these two effector proteins work together, manipulating the host cell signaling
transduction and causes host cell rounding and cell apoptosis. ExoY is an nucleotidyl cyclase
toxin that contains ATP binding domains (26). After injection into the host cell cytoplasm,
ExoY is activated by host cell filamentous actin and increases the intracellular levels of several
cyclic nucleotides (27). The increased intracellular levels of cyclic nucleotide induces the cell
death and causes tissue damage (28).

The regulatory mechanism of P. aeruginosa T3SS
T3SS master regulator ExsA
The expression of P. aeruginosa T3SS regulon genes is under the control of the
transcriptional activator ExsA (29). ExsA is an AraC family transcriptional regulator which
contains a DNA binding domain (30). The master regulator ExsA directly binds to the DNA
5

consensus sequence (TNAAAANA) in the target gene promoter regions and activates the
transcription of T3SS genes (31).
The activity and function of ExsA is post-translationally regulated by the ExsCEDA partner
switch regulatory cascade (Fig. 1.1B) (32). Under non-secreting condition, anti-activator ExsD
binds to the master regulator ExsA and form a 1:1 complex (33), the binding of ExsD to ExsA
deactivates the master regulator ExsA (34). The activity of ExsD is modulated by anti-antiactivator ExsC. ExsC is post translationally regulated by the secret regulator ExsE. Under nonsecreting conditions, ExsE binds to ExsC and prevents the anti-anti-activator binding to ExsD.
Upon T3SS triggering by a low calcium level or contact to the host cell, ExsE is secreted out
and frees the anti-anti-activator ExsC. ExsC then binds to the anti-activator ExsD, thus
releasing ExsA and activating the transcription of T3SS (33).
Transcriptional regulation of ExsA
The transcription of exsA is a fine-tuned response to various of environmental changes and
nutrient sources. The low calcium environment and presence of preferred carbon source can
activate the transcription of T3SS master regulator ExsA, thus triggering the expression of
T3SS genes (35, 36). The major regulatory pathways illustrated in Fig. 1. 2.
The expression of exsA can be activated through two different promoter regions (exsC
promoter region and exsA promoter region) in exsCEBA operon. ExsA promoter region is
controlled by Vfr (Virulence factor regulator), a homolog of Escherichia coli CRP (cAMPactivated global transcriptional regulator) transcriptional activator. In a low calcium
environment, the adenylate cyclase CyaB (the major adenylate cyclase in P. aeruginosa
required for the bacterial virulence) responds to the low calcium level and synthesizes cyclicAMP. Vfr responds directly to the increasing intracellular cyclic-AMP levels. The Vfr protein
binds directly to cAMP and undergoes conformational change. The Vfr-cAMP complex then
activates exsA transcription via binding to exsA promoter region (37, 38).
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ExsC promoter is ExsA dependent. The master regulator ExsA autoregulates its own
expression via exsC promoter region (39). Besides ExsCEDA regulatory cascade, the
transcription of exsCEBA is fine-tuned by the Cbr/Crc regulatory pathway. CbrA/B is a twocomponent regulatory system. The sensor kinase CbrA responds to non-preferred carbon
sources such as mannitol and activates the response regulator CbrB. CbrB then triggers the
gene expression of a non-coding regulatory RNA gene crcZ. The non-coding regulatory RNA
CrcZ, RNA chaperone Hfq, and Catabolite repression control protein (Crc) form a complex
and deactivate Crc activity (40). Since Crc positively regulates T3SS via enhancing the
transcription of exsCEBA operon, deactivating Crc reduces the expression of T3SS. Although
the gene expression profile analysis of crc mutant showed that Crc may regulate T3SS through
various pathways, the underlying regulatory mechanism of Crc to T3SS is largely unknown.
(36)

Post-transcriptional regulation of T3SS
RsmA (Repressor of Secondary Metabolism) is a Csr (Carbon storage repressor) family
protein (41). In P. aeruginosa, RsmA is crucial for regulating different virulence factors such
as T3SS, T6SS and motility (19, 42, 43). It is also the key regulator for switching the life style
of P. aeruginosa from planktonic to biofilm through regulating the secondary messenger
molecule cyclic-di-GMP (44).
The post-transcriptional regulator RsmA plays an important role in modulating T3SS.
Previous research demonstrated that deletion of rsmA leads to a defect in exsA at the
posttranscriptional level (45). The regulation of T3SS by RsmA is similar to the Cbr/Crc
regulatory pathway. GacS/GacA two component system regulates the T3SS via activating the
transcription of non-coding regulatory small RNAs RsmY and RsmZ. These two non-coding
regulatory small RNAs directly bind to, and deactivate RsmA (46), decreasing the intracellular
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levels of the master regulator ExsA and reducing the T3SS gene expression. There are also
other regulatory components such as AlgZR two component system and MgtE which regulate
T3SS via Gac/Rsm system. AlgZR two component system controls the alginate synthesis. Once
this two component system is activated, the response regulator AlgR increase RsmY/Z levels
through unknown mechanisms and decreases the expression of T3SS (45). The magnesium
transporter MgtE can also inhibit T3SS via activating the GacS/GacA two component system
and increasing the RsmY/Z level (47). These previous studies indicate the Gac/Rsm system is
crucial for regulating P. aeruginosa T3SS.
The translation of ExsA mRNA relies on the RNA helicase DeaD which is encoded by the
gene PA2840 in PAO1 strain (48). The deletion of deaD causes greatly reduced ExsA protein
levels and results in defects in the virulence of P. aeruginosa (49). P. aeruginosa DeaD is an
RNA helicase of the DEAD-Box protein family. This group of RNA helicases are present in a
wide range of bacteria and archaea. In prokaryotic cells, DEAD RNA helicases either unwind
short duplex RNA or stimulate the RNA degradation (50). Bioinformatic analysis and genetic
experiments showed that 37nt of exsA mRNA 5’-UTR forms an inhibitory structure that
prevents translation, however, RNA helicase DeaD relieves the structure and allows the
translation of exsA mRNA (48).

Other regulatory components regulate T3SS
There are several other regulatory components that regulate T3SS - Quorum sensing and
sigma factors RpoN negatively control the T3SS (51). A gene designated as ptrB (related to
DNA damage) suppresses the T3SS under the stress of DNA damage (52), and the multi-drug
efflux pump inhibits the T3SS (53). In addition, some environmental signals such as the oxygen
and NO level can also affect the expression of P. aeruginosa T3SS (54, 55). However, the
exact mechanism is unknown.
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The crisis of antibiotic resistance
Antibiotic resistance has become a critical public health crisis worldwide. In some areas of
the world, superbugs resistant to all existing antibiotics have been isolated (56). Therefore,
alternative anti-infection therapy with new inhibitory mechanisms and lower occurrence of
antibiotic resistance are needed. Futhermore, since lots of evidence shows that microbiota is
crucial for the health of their host (57, 58), the preservation of microbiota during infectious
disease treatments has become a major concern during the development of new anti-infection
therapy.

Antibiotic resistance
Antibiotic therapy is the most effective treatment for bacterial and fungal infectious diseases.
The current antibiotic therapy targets cellular components which are essential for cell survival
(i.e. bacterial cell wall and bacteria ribosome), however, the strong selective pressure leads to
the development of antibiotic resistance (59). Currently, antibiotic resistance has been found
in nearly all commercially available antibiotics (56). Antibiotic resistance leads to higher
medical cost, prolonged hospital stays and increased mortality. In the United States, antibiotic
resistance causes more than 23,000 deaths per year (60). A recent study conducted in America
demonstrated that from 2002 to 2014, the share of antibiotic resistant bacterial infections rose
from 5.2% to 11%. The increased antibiotic resistance costs more than $2 billion annually in
the nation (61).
P. aeruginosa is intrinsically resistant to antibiotics. Low cell wall permeability, outer
membrane and efflux systems all contribute to P. aeruginosa’s innate antibiotic resistance. All
of the major classes of antibiotics treating P. aeruginosa infection need to cross the bacterial
cell wall to reach their target, however, the low cell wall permeability limits the amount of
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antibiotics that can cross the cell wall. The outer membrane is another barrier that restricts
antibiotic penetration. Moreover, P. aeruginosa has at least four different antibiotic efflux
pump systems capable of efficiently exporting antibiotics from the cytoplasm. These three
resistance mechanisms combine together and keep the intracellular antibiotic concentration at
low levels. P. aeruginosa can also acquire resistance genes through other organisms or via
mutation in chromosomal genes (62).

Human microbiota and antibiotic therapy
Microbiota refers to all the microbes inhabiting many sites in and on multicellular organisms
(hosts). The microbiota contains host-specific microbes with various of functions. It is essential
for the health of the hosts in several different ways. It provides nutrients to the hosts, represses
pathogens and parasites, and stimulates the development of the host’s immune system (63, 64).
Recent studies done in fish models have proved that the life span of older fish can be extended
after inoculation of healthy gut microbiota from young fish (65). Other investigations on the
human microbiome suggest that the microbiota is associated with the severity of infectious
diseases (66, 67).
The use of antibiotics, especially the broad spectrum antibiotics, affects a large amount of
different bacteria species in microbiota and decreases the taxonomic richness, diversity and
evenness of host-associated microbiota. As a result, negatively impact the health status of hosts.
For example, disrupting the human microbiota can lead to some serious health problems such
as gut microbial disorders correlating with Clostridium difficile infection (68) and
inflammatory bowel disease (69). The recovery of microbiota after treatment with antibiotics
can take years which affects long term health of the patients (70).
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Targeting T3SS
As the T3SS is the primary acute virulence factor in P. aeruginosa, it is not only important
for initiating and increasing the severity of the disease via the effector protein, but also critical
for the survival of P. aeruginosa in the early stages of infection (71). Thus, inhibiting the T3SS
is an excellent strategy for developing new anti-infection therapy. Several studies have shown
that disarming the pathogen’s T3SS reduces bacterial virulence and disease severity (20).
Moreover, targeting the virulence factors of the pathogen has the potential advantage to
minimize the damage to the host microbiota (72).
In our lab, we screened a compound library and looked for compounds which inhibits P.
aeruginosa T3SS but not the bacterial growth. We discovered a potent P. aeruginosa T3SS
inhibitor named 187R that can silence the T3SS. In this research, we determined the molecular
mechanism of 187R inhibiting the T3SS. It has been long discussed whether anti-virulence
drugs can preserve the microbiota better than antibiotics. In this research, we have also explore
the impact of anti-virulence compound 187R on the microbiota of Arabidopsis thaliana, one
of the hosts of P. aeruginosa.
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Figure 1.1 The structure and regulatory of T3SS (A) T3SS secretion system of P. aeruginosa. (B) ExsCEBA
regulatory cascade. ExsA is the master regulator of T3SS. Under non-secretion conditions, ExsE binds to ExsC,
ExsD binds to ExsA and deactivate ExsA. Once in contact with the host cell, T3SS secretes ExsE and releases
ExsC. ExsC then binds to ExsD and frees ExsA, as a result, activating the T3SS gene expression. (Galle M. et,
al., 2012) IM: inner membrane; PG: periplasm; OM: outer membrane.
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Figure 1.2 Major regulatory pathways modulating T3SS in P. aeruginosa. CbrA/CbrB two component system
activates CrcZ non-coding small RNA and deactivates Crc which positively regulates T3SS. ExsCEDA
regulatory cascade positively regulates T3SS by free ExsA. These two pathways activate the T3SS via
activating the transcription of the exsCEBA operon through the exsC promoter. Vfr-cAMP responds to the
increasing intracellular cAMP level and binds to the exsA promoter region and activates exsA expression.
Similar to the Cbr/Crc pathway, two-component system GacS/GacA activates the transcription of two noncoding small RNA and deactivates the posttranscriptional regulator RsmA which positively regulates T3SS.
DeaD is the RNA helicase required for stimulating the translation of ExsA mRNA. Dashed line indicates that
the regulatory mechanism is not completely understood.
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Chapter 2 : Discovery of new T3SS
inhibitor and its mechanisms of T3SS
inhibition
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Abstract
Antibiotics have been widely used for treating bacterial infectious diseases. However,
traditional antibiotic therapies target the essential cell components, and this strong selective
pressure leads to the antibiotic resistance. To overcome or evade the emerging antibiotic
resistance crisis, new alternative strategies for fighting the bacterial infection is needed.
Pseudomonas aeruginosa is an opportunistic human pathogen resistant to a variety of
commonly used antibiotics. According to World Health Organization (WHO) report, P.
aeruginosa is one of the three ‘top priority antibiotic-resistant pathogens’ that pose the greatest
threat to human health. Therefore, new antimicrobial agents with new inhibitory mechanisms
are urgently needed for treating P. aeruginosa infection. Type 3 secretion system (T3SS) is the
major virulence factor of P. aeruginosa required for the initiation of infection and bacterial
survival in the epithelial airway. Therefore, targeting T3SS is a promising alternative strategy
for new drug development. In this study, we identified a potent T3SS inhibitor, designated
187R, inhibit T3SS but not the growth of P. aeruginosa by screening a compound library. The
compound greatly reduced the T3SS expression and attenuated P. aeruginosa T3SS-mediated
cytotoxicity towards HeLa cells. Examining the regulatory components and pathways of P.
aeruginosa T3SS with the presence of the 187R showed that 187R silences the P. aeruginosa
T3SS through post-translationally decreasing protein level T3SS master regulator ExsA. The
inhibitory mechanism of 187R on ExsA is independent of the known major T3SS regulatory
pathways.

Introduction
Pseudomonas aeruginosa is an opportunistic pathogen that causes acute and chronic
infections in immunocompromised patients (3). A primary virulence factor for this pathogen is
the type III secretion system (T3SS). T3SS is a needle-like structure that directly translocates
15

the effector proteins (toxins) from the bacterial cytoplasm into the host cells (23). In P.
aeruginosa, four effector proteins named ExoS, ExoT, ExoY and ExoU have been discovered
(25). These effector proteins manipulate signal transduction in the host cells, resulting in
attenuated host immune responses and increased severity of disease (28).
P. aeruginosa T3SS consists of over 40 genes organized within 10 transcriptional units. The
expression of all 10 transcriptional units are under the control of master regulator ExsA - an
AraC family transcriptional activator (30). Two monomers of ExsA bind to the consensus
sequence (TNAAAANA) in the target gene promoter regions to recruit RNA polymerase and
activate the transcription of T3SS genes (31). The activity and function of ExsA is posttranslationally regulated by the ExsCEDA regulatory cascade (32). While triggered by the low
calcium level or contact to the host cell, ExsE is secreted which frees the anti-anti-activator
ExsC. ExsC then binds to the anti-activator ExsD which releases ExsA to turn on the expression
of the T3SS (33). ExsA also autoregulates the transcription of itself by binding to the promoter
region of exsCEBA operon (39). Besides the ExsCEDA regulatory cascade, exsA is modulated
by several other pathways including the Vfr-cAMP pathway, Cbr/Crc pathway, and RsmY/Z/A
pathway (35, 55, 73). In a low calcium environment, Vfr (Virulence factor regulator) responds
directly to the increasing intracellular cyclic-AMP levels and activates exsA transcription via
binding to exsA promoter region (37, 38). Catabolite repression control protein (Crc) is another
positive regulator that regulates exsA through enhancing exsCEBA expression (36). The activity
of Crc is controlled by non-coding regulatory small RNA CrcZ (74). The expression of crcZ is
triggered by the CbrA/B two-component system which senses and responds to non-preferred
carbon sources such as mannitol. The non-preferred carbon sources stimulate the two
component system and activates the transcription of crcZ. CrcZ RNA binds to Crc protein and
deactivates the protein with the assistance of RNA chaperone Hfq (75, 76).
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The post-transcriptional regulator RsmA also plays an important role in modulating the
T3SS. Similar to the Cbr/Crc regulatory pathway, the GacS/GacA two component system
regulates the T3SS via activating the transcription of non-coding small RNAs RsmY and RsmZ.
These two small RNAs deactivate RsmA which is the posttranscriptional activator for T3SS
(46). Although the regulatory mechanism is not well understood, previous research
demonstrated that deletion of rsmA showed a defect in ExsA at the posttranscriptional level
(45). Another important regulatory component stimulates the translation of exsA independent
of RsmA is RNA helicase DeaD. DeaD unwinds 5’ UTR of ExsA mRNA and allows the
imitation of translation. (48). The deletion of deaD greatly reduced ExsA protein levels and
resulted in defect in the virulence of P. aeruginosa (49).
Since Alexander Fleming discovered penicillin in 1928, antibiotic therapy has been widely
used for treating bacterial infections. However, the current antibiotic therapy targets the cellular
components which are essential for cell survival (i.e. bacterial cell wall and bacteria ribosome).
The strong selective pressure leads to the development of antibiotic resistance (59). Currently,
antibiotic resistance has been found in nearly all commercially available antibiotics (56).
Pseudomonas aeruginosa is resistant to a variety of commonly used antibiotics such as
carbapenem. According to World Health Organization (WHO) report, P. aeruginosa is one of
the three ‘top priority antibiotic-resistant pathogens’ that pose the greatest threat to human
health (77). New antimicrobial agents with new inhibitory mechanisms are urgently needed for
treating P. aeruginosa infection. In addition, antibiotic therapy can alter human microbiota and
affects host health status in the long term. In some cases, disturbing the human microbiota is
associated with several serious diseases; for example, gut microbial disorder correlates with
Clostridium difficile infection (68) and inflammatory bowel disease (69).
Therefore, alternative anti-infection therapies, which can preserve the microbiota and lower
the occurrence of antibiotic resistance, are needed. T3SS is a major virulence factor in P.
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aeruginosa. It is not only critical for initiating the infection but also responsible for killing the
hosts’ immune cells. Therefore, inhibiting T3SS decreases the bacterial survival in hosts and
reduces the severity of the diseases (71). Moreover, targeting the virulence factors of the
pathogen has the potential advantage of minimizing the damage to the host microbiota (72).
Various T3SS inhibitors, including several small-molecule inhibitors and a monoclonal
antibody, have been developed during the last decade. These T3SS inhibitors target for
different T3SS components, such as the extracellular structural components, effector proteins
and intracellular regulatory proteins (78). One group of extracellular structural components
used as targets of the inhibitors is the traslocon proteins. Previous research showed that the
Phenoxyacetamide inhibitors and monoclonal antibody KB001-A target the needle structural
protein PscF and needle tip protein PcrV, respectively (21, 79). The interaction of the
compound and needle structural protein block the translocation of the effector proteins, greatly
reducing the virulence of P. aeruginosa. The small molecule Pseudolipasin is able to inhibit
the ExoU PLA2 activity and ExoS ADP-ribosyltransferase activity respectively (80, 81). In
vitro experiments have proved that these two anti-effector molecules neutralize the toxicity of
T3SS effector and protect the CHO cells. However, these two strategies all have their
limitations since 1) inserting the needle of T3SS itself can cause damage to the host cells, and
2) different P. aeruginosa strains carry different sets of effector proteins (23). An attractive
target for developing T3SS inhibitors is the master regulator ExsA. Since all the P. aeruginosa
T3SS genes are ExsA-dependent, inhibiting the synthesis or activity of ExsA would lead to the
decrease or complete elimination of all T3SS gene expression.
In the present work, we screened a compound library and search for compounds inhibit P.
aeruginosa T3SS but not the bacterial growth. We discovered a potent P. aeruginosa T3SS
inhibitor named 187R. The compound strongly inhibits the T3SS while not affecting the growth
of P. aeruginosa. In vitro HeLa cell infection assay suggested 187R reduced T3SS-mediated
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cytotoxicity in the assay. Further research demonstrated that 187R dramatically decreased the
protein level of ExsA through post-translational mechanism.

Materials and Methods

Bacterial strains, plasmids, primers, and growth condition.
Bacterial strains and plasmids used in this study are listed in Table 2.1. E. coli and P.
aeruginosa were routinely cultured in LB medium at 37°C unless otherwise stated. LB
supplemented with 200 mM NaCl and 10 mM nitrilotriacetic acid (NTA) were used as the
T3SS inducing medium. Antibiotics were used at the following concentrations: 100 µg/mL of
carbenicillin (Cb), 10 µg/mL of gentamicin (Gm), 10 µg/mL of tetracycline (Tc) for E. coli and
100 µg/mL of Cb, 50 µg/mL of Km, 50 µg/mL of Gm and 30µg/mL of Tc for P. aeruginosa.
Primers used for PCR are listed in Table 2.2.

Screening for P. aeruginosa T3SS inhibitors
The P. aeruginosa strain PAO1 harboring exoS-gfp (Green fluorescent protein)
transcriptional fusion reporter plasmid was used for screening the T3SS inhibitors. Overnight
culture of PAO1 harboring the reporter plasmid at a 1:1000 was inoculated into T3SS inducing
medium with 250 µM of the screening compound. P. aeruginosa treated with DMSO (solvent
for screening compounds) was used as negative control. Bacteria were cultured at 37°C for
seven hours before harvesting. The harvested bacterial cells were diluted in PBS and the GFP
intensity was measured using fluorescence-activated cell sorter (FACS) flow cytometry (BD
Biosciences, CA).
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Western blotting
5µL of PAO1 overnight culture was inoculated into 5 mL T3SS inducing medium with 250
µM of the screening compound. DMSO was used as control. Bacterial cell pellets and
supernatant were separated by centrifugation at seven hours post-inoculation. For measuring
the ExoS and ExsA protein in the bacteria cell, the cell pellets were resuspended in 50 µL of
PBS. 50 µL of 2X SDS-page buffer was added into each sample and followed by boiling for
10 minutes. For measuring the secreted ExoS protein level in the supernatant, the supernatant
collected from the previous step was centrifuged again to remove any remaining cells.
Trichloroacetic acid was added into the supernatant to reach the concentration of 10% and
followed by centrifugation at 13,500 rpm for 30 min to collect the secreted protein. The protein
pellets were resuspended in 2x SDS-page buffer. The protein sample from equal amount of
cells were loaded on SDS page gel. The proteins were transferred to polyvinylidene difluoride
(PVDF) membrane and probed with a rabbit polyclonal antibody against ExsA or a chicken
polyclonal antibody against ExoS. A mouse antibody against RNA polymerase was used as
control for the total protein quantity.

HeLa cell cytotoxicity assay
T3SS-mediated cytotoxicity was determined by a cell lifting assay. HeLa cells (1´105) were
seeded in each well of a 12 well plate and cultured for 18 hours at 37°C with 5% CO2 in DMEM
medium (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal bovine
serum, penicillin (100 Units/mL), and streptomycin (100 µg/mL). Before the infection assay,
the HeLa cell culture medium was removed from the well and the cells were washed twice with
PBS (Phosphate Buffered Saline). HeLa cell culture medium without antibiotic supplemented
with 250 µM of compound or DMSO, was added into each well. Bacteria were cultured
overnight in LB medium at 37 °C. After collecting the overnight culture by centrifugation. The
bacteria cell pellet was washed with PBS and resuspended in DMEM. HeLa cells were then
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infected with the bacteria at MOI (Multiplicity of infection) of 30. Three and half hours post
infection, the medium were removed and the HeLa cells were stained by crystal violet after
rinsing twice with PBS. The plate was washed twice with PBS and then 200 µL of 95% ethanol
was added to the wells for dissolving the crystal violet. The OD490 of the ethanol solution with
dissolved crystal violet was measured to determine the cells that were attached to the surface.

Mutant strain and reporter plasmid construction
To construct the deaD deletion mutant, a PCR fragment consisting of the flanking region of
~900 bp up and down stream of deaD were cloned into the HindIII and BamHI restriction site
of pEX18GM. The plasmid was transferred to P. aeruginosa PAO1 strain by conjugal mating
as previously described (82).
The GFP reporter plasmid was constructed by cloning promoter regions of exsC, exsA, exoY
and exoT into pProbe-AT, a broad host range vector with a promoterless GFP (green
fluorescent protein) (83), respectively. The promoter activity was monitored by measuring GFP
intensity using flow cytometry as described earlier.
For constructing the tssA1‘-’lacZ, exsA‘-’lacZ and exsCEBA‘-’lacZ translational fusion
reporter plasmid, 5’UTR and first 25 codons of tssA1 gene, 5’UTR and first 52 codons of exsA,
region between exsC transcriptional start site to 52 codons of exsA were amplified by PCR,
respectively, and cloned into the translational lacZ fusion vector PSW205 (84). The forward
oligonucleotide primers for constructing these two translational fusion reporters were
engineered to include an EcoRI restriction site and a lacUV5 promoter. Since there is no lacI
gene in P. aeruginosa, IPTG inducing is not necessary. The expression of the translational
fusion reporters were measured by β-Galactosidase activity as previously described (51).

21

qRT-PCR analysis
The mRNA levels of exsA were measured by qRT-PCR. Bacterial cells cultured in T3SS
inducing medium for 7 h were harvested. RNeasy mini kit (Qiagen, Hilden, Germany) was
used to isolate the total RNA. cDNA was synthesized using iScript cDNA synthesis kit (BioRad Laboratories, Hercules, CA). The cDNA level of exsA gene was quantified by qRT-PCR
using SYBR green master mix (Applied Biosystems, CA). Data were analyzed using a
Relative Expression Software Tool (85).The expression level of rpsL was used as an
endogenous control for data analysis (36).

Motility assay
Swarming. Swarming plates were prepared as previous described (86). 187R (250 µM) or
DMSO were adding into the medium. P. aeruginosa from overnight LB agar was inoculated
on the plate. After overnight incubation at 30°C. The diameters were measured.
Twitching. LB broth solidified with 1% (wt/vol) agar was used for twitching motility. P.
aeruginosa was stab inoculated to the bottom of the petri-dish. 187R (250 µM) or DMSO was
added into the medium. After inoculation for 16 hours at 37°C, the medium was removed from
the plate. The zone of motility at the agar/Petri dish interface was measured after staining with
crystal violet.

Biofilm assay
Quantification of biofilm was performed in 96 well microtiter plates. Bacterial cells from
overnight cultures were inoculated at 1:100 dilution into T3SS inducing medium or ABTGC
medium (87). The plate was incubated overnight at 37°C without shaking. Biofilms were
stained with 0.1% crystal violet and were washed with water to remove unbound dye, and the
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crystal violet was dissolved in 95% ethanol and the absorbance at 570 nm was measured. For
each treatment, six independent experimental repeats were performed.

Minimal inhibition concentrations (MICs)
Determination of the minimum inhibitory concentration (MIC) for antibiotics was
performed in LB broth as previously described (88).The lowest antibiotic concentration that
showed no growth was considered as the MIC.

β-Galactosidase Assays
β-Galactosidase assays were carried out in triplicate. The activity was determined as
described (89). The samples were collected by centrifuge. The cell pellets were rinsed and
resuspended in PBS to washed off the compound. The expression levels of the reporter
plasmids were determined by normalization of β-Galactosidase activity (OD420) to the bacterial
growth (OD600).

Statistical Analysis
Two-tailed student’s t-test was used to assess the inhibition of 187R on the T3SS gene
expression. One way analysis of variance (ANOVA) combined with Tukey-HSD were
applied for multiple comparisons. The test was performed by statistic software R (90).

Results
Screening inhibitors of P. aeruginosa T3SS
To discover the compound inhibit T3SS but not the growth of P. aeruginosa, we screened a
small molecule compound library. The compound library was consisted by salicylic acid, its
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precursors and their analogues. A total of 264 small molecule compounds were screened for
identifying the inhibitors of P. aeruginosa T3SS.
For monitoring the expression of exoS under the T3SS inducing condition (200 mM NaCl
and 10 mM nitrilotriacetic acid), a GFP reporter carrying the exoS promoter region (59) was
used in the screening process. Each compound was dissolved in DMSO and was added into the
medium at a concentration of 250 µM. Bacteria cells were harvested seven hours post
inoculation and the Mean Fluorescence Intensity (MFI) was measured by flow cytometry. The
MFI of DMSO (vehicle dissolve the compound) treated reporter strain was used as control.
Among all the compounds screened, compound 187 strongly inhibited the expression of exoS
(90% inhibitory at concentration of 250 µM) in contrast to the DMSO treatment. Further
analysis of two different 187 conformational isomers showed that only 187R inhibits the exoS
while 187S does not (Fig. 2.1A). Also, no inhibition of bacterial growth was observed upon
the addition of 250 µM of compound 187R (Fig. 2.1B). The dose-dependent effectiveness of
187R on P. aeruginosa exoS promoter activity was examined in a T3SS inducing medium
supplemented with different concentrations of 187R. As shown in Fig. 2.1C, the minimal
concentration of 187R required to reach its maximum inhibition of the exoS promoter activity
is 35 µM.

187R impaired T3SS expression and reduced the virulence of P. aeruginosa
To further examine the effect of 187R on P. aeruginosa T3SS, the expression levels of two
effector encoding genes, exoY and exoT, were measured. The results indicated that the promoter
activities of both genes were decreased when exposed to 187R (Fig.2.2A and B). In addition,
a Western blot was performed to determine the ExoS protein (48.3kDa) level in the cell pellet
and the supernatant. An anti-ExoS polyclonal antibody was used in the Western blot. Similar
to previous studies the anti-ExoS polyclonal antibody also cross-reacted to the ExoT (59, 91)
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showing another band at around 48kDa. As shown in Fig. 2.2C, consistent with the exoS and
exoT promoter activity, ExoS and ExoT protein levels were reduced in the presence of 187R
in both bacteria culture supernatant and cell pellets.
Previous reports showed that P. aeruginosa T3SS translocates effector proteins into the
cytoplasm of host cells and causes cell rounding, lifting, and death (92, 93). The infected cells
detach from the monolayer culture, which allows us to evaluate the efficacy of T3SS inhibitors
by a HeLa cell lifting assay (93). Briefly, the HeLa cells were infected with P. aeruginosa at a
multiplicity of infection (MOI) of 30 in the presence of 187R. We added DMSO as a control.
After incubation for three and half hours, the cell culture was rinsed twice with PBS and the
living cells attached to the surface were stained with crystal violet. After removing the unbound
crystal violet, 200 µL of ethanol was added. The dissolved crystal violet was measured by
absorbance at a wavelength of 490 nm. In this assay, we used PAK strain since 1) it has higher
and earlier T3SS expression than the PAO1 strain (94); 2) its T3SS repressed by 187R. A T3SS
defect strain, pscJ mutant strain, was used as a control. pscJ is a gene which encodes a
lipoprotein component of the T3SS basal substructure of the needle complex. It is required for
the assembly of a functional T3SS (26). Consistent with the previous research (71), deletion of
pscJ greatly decreased virulence compared to wild type PAK. In addition, adding 187R
significantly reduced the cytotoxicity of PAK wild-type while showing no T3SS-mediated
cytotoxicity to HeLa cells. The cell morphology after P. aeruginosa inoculation also confirmed
that T3SS-mediated cell rounding greatly reduced when 187R was supplemented (Fig. 2.3BD). In conclusion, these results demonstrated 187R is a potent P. aeruginosa T3SS inhibitor.

187R did not affect Vfr-cAMP pathway
Transcriptional regulator protein Vfr (virulence factor regulator) activates P. aeruginosa
T3SS through cyclic AMP dependent pathway. Previous research demonstrated that Vfr-cAMP
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complex autoregulates vfr gene expression by directly binding to its own promoter region (35).
To test if 187R inhibits T3SS through Vfr-cAMP pathway, vfr promoter activity was measured
in the present of 187R. vfr mutant was used as a control in the experiment. In agreement with
the previous research, mutation of vfr greatly reduced vfr promoter activity, indicating that Vfr
is involved in autoregulation (Fig. 2.4A). However, in the wild-type strain, 187R did not alter
the vfr promoter activity compared to the DMSO control (Fig. 2.4A). This result suggested that
187R does not inhibit P. aeruginosa T3SS through Vfr-cAMP pathway. To further confirm
this conclusion, we tested the exsA promoter activity in the presence of 187R. Previous research
states that Vfr-cAMP complex directly binds to T3SS master regulator exsA promoter region
and activates the transcription of exsA. The low exsA promoter activity in vfr mutant was
observed as previously described (38), which proved that Vfr positivly regulates exsA promoter
activity. However, we found that there were no significant changes in exsA promoter activity
when treated with 187R (Fig. 2.4B). These results suggested that 187R did not affect the VfrcAMP pathway.

187R did not inhibit T3SS through Cbr/Crc pathway
P. aeruginosa regulates T3SS through the Cbr/Crc pathway in which Crc (catabolite
repression control protein) serves as a positive regulator of T3SS and modulates the
transcription of exsCEBA (36). Therefore, if 187R inhibits T3SS through the Cbr/Crc pathway,
exsC promoter activity should reduce. Consistent with the previous results, in a crc mutant
strain, exsC promoter activity greatly reduced compared to the wild type (Fig 2.5A). However,
we found that the exsC promoter activity was not altered when treated with 187R (Fig. 2.5B).
Crc represses the translation of amiE, which encodes an aliphatic amidase (74). Using the
amiE‘-’lacZ translational fusion reporter, we found that amiE‘-’lacZ expression did not show
significant differences between DMSO and 187R treated wild type strains (Fig. 2.5C). Similar
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to previous research, there was a significant increase of amiE‘-’lacZ expression in the crc
mutant strain (74). In conclusion, these results confirmed that 187R did not inhibit T3SS via
the Cbr/Crc pathway.

187R increases the RsmY level in P. aeruginosa
RsmY and RsmZ small RNAs play crucial roles mediating various cellular processes
including T3SS in P. aeruginosa (45). We first tested the mRNA levels of two regulatory small
RNAs RsmY and RsmZ via qRT-PCR. As shown in Fig. 2.6, rsmY RNA level increased
dramatically (four-fold increase in 187R-treated bacteria) while rsmZ RNA level has a
moderate decreased in the presence of 187R. This result suggested that rsmY could be the
potential target causing the inhibition of T3SS.

187R inhibits P. aeruginosa T3SS not through RsmY/Z/A regulatory pathway
Since rsmY small RNA inhibits T3SS by adjusting the activity of RsmA protein, we tested
the activity of RsmA. Previous studies showed that increased RsmA activity elevates T3SS and
represses T6SS at the post-transcription level. As a repressor for T6SS, RsmA binds to the
GGA motif of P. aeruginosa T6SS mRNAs to repress the translation of T6SS genes. The tssA1
is a gene that encodes a T6SS structural protein. It has a GGA motif and its translation is
repressed by RsmA (95, 96). To evaluate the RsmA activity, a tssA1‘-’lacZ translational fusion
reporter was constructed by cloning the 5’ UTR and the first 25 codons of tssA1 into pSW205.
The tssA1‘-’lacZ translational fusion reporter is driven by lacUV5 promoter. If 187R inhibits
T3SS via RsmY/Z/A regulatory pathway, an increasing tssA1‘-’ lacZ expression level will be
observed in the presence of 187R. However, as shown in figure 2.7A, the expression level of
tssA1‘-’lacZ decreased moderately in the presence of 187R, suggesting elevated RsmA activity.
This data demonstrated that the 187R did not inhibit T3SS through RsmY/Z/A regulatory
pathway. To further confirm the increased rsmY small RNA in the presence of 187R did not
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inhibit the T3SS expression, we checked the T3SS expression under a rsmYrsmZ double mutant
background within the presence of 187R. The result showed that 187R still strongly inhibits
the exoS promoter activity (Fig. 2.7B), which confirmed that 187R did not inhibit T3SS through
RsmY/Z/A regulatory pathway.

187R inhibits T3SS not through reducing Lon protease activity
Since the increasing RsmY did not affect T3SS, we examined the other regulatory
components that can increase RsmY RNA levels and are capable of inhibiting T3SS
independent of RsmA. One possible cellular component that may cause the increase of rsmY
but not rsmZ RNA and inhibits the T3SS independent of RsmY/Z/A regulatory pathway is the
Lon protease (97). Lon protease is an important enzyme involved in the protein quality control
in microorganisms and required for full virulence of P. aeruginosa (98). Previous research
suggested that Lon protease not only positively regulates T3SS through unknown mechanisms,
but also negatively regulates the rsmY mRNA level through adjusting the protein level of RNA
chaperon Hfq (99). If the compound 187R suppressed the T3SS through inhibiting Lon
protease, the RNA chaperon Hfq would increase and elevate the rsmY but not rsmZ RNA level
(100). Since Lon protease represses the expression level of quorum sensing autoinducer
synthetase rhlI (101), we first performed qRT-PCR to find out if the mRNA level of rhlI is
increased in the presence of 187R. The qRT-PCR results showed that rhlI mRNA levels
decreased while adding 187R in the medium (Fig. 2.8). Lon protease is also involved in
fluoroquinolone class antibiotic resistance. Mutation of lon resulted a four times increasing of
ciprofloxacin susceptibility compared to the wild type (102). If 187R inhibits Lon protease, we
would observe the reduction of ciprofloxacin MIC while adding 187R. However, the MIC of
ciprofloxacin did not change after adding 187R (Table 2.3). These results demonstrate that
187R does not inhibit T3SS through Lon protease.
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187R inhibits T3SS not through increasing the secondary messenger c-di-GMP level
Besides the Lon protease, another potential candidate that may cause the increasing rsmY
(but not rsmZ) mRNA level is the diguanylate cyclase (DGC) HsbD. HsbD positively regulates
rsmY transcription through increasing the intracellular c-di-GMP level (103). C-di-GMP is an
important intracellular secondary messenger that regulates multiple virulence factors. T3SS is
one of the virulence factors modulated by c-di-GMP. Although the mechanisms how c-di-GMP
regulates T3SS is not completely understood, c-di-GMP negatively regulates T3SS. To
measure the c-di-GMP level in the presence of 187R, we examined the cdrA promoter activity,
which is positively regulated by the intracellular c-di-GMP level (104). Our result showed that
cdrA promoter activity did not increase in the presence of 187R (Fig. 2.9A). In P. aeruginosa,
increasing intracellular c-di-GMP represses swarming motility but promotes twitching motility
(103). In order to further confirm that intracellular c-di-GMP level was not affected by 187R,
the twitching and swarming motility of P. aeruginosa was examined in the presence of 187R.
Our results showed that twitching motility (Fig. 2.9B-C) did not change while adding 187R in
the medium. These results suggested that 187R did not inhibit the T3SS through increasing
intracellular c-di-GMP level.

187R inhibits T3SS through post-translationally regulating the master regulator ExsA
For elucidating the impact of 187R on master regulator exsA, Western blots of ExsA was
performed using anti-ExsA antibody. Western blot of ExsA protein showed that the ExsA
protein level decreased dramatically in the presence of 187R (Fig. 2.10A). Since our results
also indicated that exsA and exsC promoter activity was not altered by 187R (Fig. 2.4B & Fig.
2.5B), we investigated the inhibitory mechanisms of 187R on exsA at post-transcriptional level.
We measured the exsA mRNA in the presence of 187R or DMSO using qRT-PCR. As shown
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in Fig. 2.10B, the ratio of mRNA level in the presence of 187R and DMSO is close to one,
revealing the similar exsA mRNA level in the presence of 187R or DMSO.
An alternative hypothesis to account for 187R decreasing ExsA protein level could be that
187R hampered the translation of exsA mRNA. To test this hypothesis, we first tested if 187R
affects the activity of RNA helicase DeaD. DeaD is the major RNA helicase that stimulates
exsA translation independent of RsmA (48). To examine whether 187R inhibits the T3SS via
DeaD, we first determined the T3SS expression level under the deaD mutant background. The
exoS-gfp transcriptional fusion reporter was introduced into the deaD mutant strain. Consistent
with previous research, ExsA-dependent exoS gene expression was extremely low in the deaD
mutant, indicating the T3SS expression was abolished in this mutant (Fig. 2.11A). Therefore,
we were unable to compare the T3SS expression between 187R and DMSO treatments under
deaD mutant background.
An alternative strategy for testing whether DeaD is affected by 187R is observing the growth
of bacteria at low temperature. P. aeruginosa deaD is a homologue of E.coli deaD which is
essential for low temperature growth (50). In order to confirm deaD plays the similar role in P.
aeruginosa, we measured the growth of P. aeruginosa deaD mutant strain under low
temperature conditions (16°C) in both T3SS inducing medium and non-inducing (LB) medium.
Similar to the E.coli deaD mutant, P. aeruginosa deaD mutant showed a growth defect at 16°C
but not 37°C (Fig. 2.11B-D). Therefore, if 187R inhibits exsA translation by reducing DeaD
activity, a reduced growth at 16°C would be observed when 187R was added into the growth
medium. However, adding 187R did not affect the growth of the wild type strains at 16°C in
both T3SS inducing and non-inducing conditions (Fig. 2.11C-D). As a result, we conclude that
187R does not inhibit T3SS through affecting the RNA helicase DeaD.
The transcription of exsA can be activated by ExsA through the exsC promoter region and
Vfr-cAMP through the exsA promoter region, therefore, generating exsCEBA polycistronic
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mRNA and exsA mRNA. Since the regulatory mechanisms of these two different mRNAs have
not been completely understood, two different translational fusion reporters, exsCEBA‘-’lacZ
and exsA‘-’lacZ, were constructed. As show in the Fig. 2.12A, exsCEBA‘-’lacZ translational
fusion reporter was constructed by cloning the region between the transcriptional start site of
exsC to 52 codons of exsA into pSW205. exsA‘-’lacZ translational fusion reporter was
constructed by cloning the 5’ UTR of exsA and 52 condons of exsA into pSW205 (Fig. 2.12A).
These two exsA‘-’lacZ and exsCEBA‘-’lacZ translational fusion were driven by foreign
lacUV5 promoter. In the presence of 187R, the expression of exsA‘-’lacZ and exsCEBA‘-’lacZ
translational fusion reporter were not reduced (Fig. 2.12B-C). In conclusion, the results above
suggested that compound 187R suppresses ExsA protein but it is not through decreasing the
transcription and translation of exsA.

187R inhibits T3SS not through nitrate reductase (NirS)
We also studied whether 187R inhibits the T3SS via nitrate reductase NirS which is required
for the maximal virulence of T3SS (54). Previous study showed supplementation with sodium
nitroprusside (SNP) as NO donor restored T3SS in a NirS mutant (54). Therefore, if the
compound inhibits T3SS via NirS, supplementation with SNP as an NO donor would restore
the T3SS with the presence of 187R. As shown in Fig. 2.13, supplementation with SNP did not
restore the T3SS expression in the presence of 187R. In addition, the NirS mutant only showed
decreased T3SS-mediated cytotoxicity when the MOI = 0.1. In our HeLa cell lifting assay, we
used much higher MOI (MOI=30) for our assay and 187R showed significant inhibition of
T3SS-mediated cytotoxicity. Therefore, NirS is not the target of 187R.

187R inhibits T3SS not through ppGpp
5’-diphosphate-3’-diphosphate (ppGpp) is another bacteria secondary messenger that
regulates the virulence of bacteria. Although the regulatory mechanisms is not clear, this
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secondary messenger is also involved in motility, biofilm formation and T3SS. In a ppGpp
deficient strains, the swarm motility and biofilm formation are greatly reduced. Since we did
not observe a reduced swarming motility in the presence of 187R, the compound probably did
not affect the T3SS by reducing ppGpp level. Our biofilm formation assay (Fig. 2.14A-B) also
found that the biofilm formation was not altered by 187R in both T3SS-inducing medium and
ABTGC medium. These results suggested that 187R did not inhibit the T3SS by decreasing
ppGpp.

Discussion
P. aeruginosa is resistant to many commonly used antibiotics. Since the T3SS is essential
for initiating the acute infection and responsible for bacterial survival in epithelial airway (71),
it has been considered as a potential alternative target for the development of new antimicrobial
therapies. In this study, we screened a compound library to look for the anti-virulence
compounds that inhibit P. aeruginosa T3SS but do not inhibit the growth of the bacteria. We
found a potent T3SS inhibitor, 187R, that can suppress the P. aeruginosa T3SS. Our data
suggested that the compound reduces the T3SS-mediated cytotoxicity towards HeLa cells.
Further research proved that adding the compound did not inhibit T3SS through the major
regulatory pathways including Cbr/crc, Vfr/cAMP and RsmY/Z/A regulatory pathway. We
also confirmed that 187R did not inhibit T3SS through Lon protease, diguanylate cyclase (DGC)
HsbD, or nitrate reductase NirS. The impact of the compound 187R on the master regulator
ExsA was also assessed. Our data demonstrated that 187R dramatically reduced protein level
of ExsA without inhibiting exsA gene expression and translation. These results indicate that
there may be an unknown regulatory component that post-translationally regulates ExsA
protein levels independent of the major regulatory pathways.
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In this study, supplementation of 187R greatly reduced the protein level of ExsA and
dramatically decreased the expression of ExsA-dependent genes such as exoS and exoY.
However, the reduced ExsA protein level did not decrease the exsC promoter activity and exsA
mRNA level. The phenotype was probably caused by the high binding affinity of ExsA to exsC
promoter region (29). Therefore, the promoter activity of exsC was not affected by the
decreased ExsA protein level. In addition, we found that although adding 187R elevates the
RsmY RNA level, the increased RsmY RNA level did not sequester the RsmA and resulted
defected exsCEBA‘-’lacZ expression. A plausible explanation for this observation is that 187R
may increase the protein level of the RNA chaperone Hfq. While Hfq and RsmA shared
overlapping binding sites on rsmY small RNA, the binding affinity of Hfq to rsmY small RNA
is higher than RsmA to rsmY small RNA. As a result, although the binding of Hfq to RsmY
increased the RNA stability, it prevents RsmA from binding to rsmY small RNA (105). A
further study on the effect of 187R on Hfq is needed to confirm the above hypothesis.
P. aeruginosa uses various planktonic virulence factors to initiate the infection in tissues
(106). When the bacterium is under stress or unfavorable conditions, it turns off the planktonic
virulence factors and switches the lifestyle from planktonic to biofilm. Eventually, the
bacterium establishes the biofilm-based chronic infection. Clinically, treating the biofilmassociated infections is a tremendous challenge due to its higher tolerance to antibiotics and
lower susceptibility to the host immune response (107). While P. aeruginosa shifts from
planktonic lifestyle to biofilm, some regulatory components switch acute virulence factors and
biofilm formation. For example, RsmA, the positive T3SS posttranscriptional regulator,
negatively regulates biofilm formation through various regulatory pathways including
controling intracellular c-di-GMP level (44). Previous research conducted in a murine lung
infection model showed that although disrupting rsmA reduced the acute virulence factors, the
mutant showed increased biofilm formation and increased pulmonary inflammation in a
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chronic infection model (44, 108). Therefore, while screening the anti-virulence compounds
like T3SS inhibitors, it is important to avoid the compounds impacting the cellular components
that inversely control acute virulence factors and biofilm formation such as RsmA. Our data
suggests that 187R did not inhibit T3SS via reducing RsmA activity or increasing c-di-GMP
level. Further experiments showed that 187R did not promote the biofilm formation compared
to the DMSO control (Fig. 2.14). Our results suggest that while 187R strongly inhibits the
T3SS of P. aeruginosa, the compound does not increase biofilm formation.
Taken together, our research suggested that the compound 187R inhibits P. aeruginosa T3SS
through reducing ExsA protein level at post-translational level. After examining the current
known mechanism, we found that 187R did not inhibit T3SS through major known regulatory
pathways or components. These results indicate that there is an unknown T3SS regulatory
pathway way that regulates ExsA protein at the post-translational level. Moreover, 187R has
not only shown inhibition to T3SS, further research suggested that 187R does not promote the
other virulence factors such as motility, c-di-GMP and biofilm formation. Overall, 187R is a
potential compound for further drug development.
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Figure 2.1 Effect of 187 on P. aeruginosa exoS promoter activity and growth. P. aeruginosa was cultured in
T3SS inducing media supplemented with 250µM of compound 187R or DMSO. (A) exoS promoter activities
supplemented with 187R and DMSO respectively. (B) Growth of P. aeruginosa with 250µM of 187R compared
with DMSO. (C) Evaluation of the dose-dependent effect of 187R on exoS expression.
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Figure 2.2 187R impairs T3SS expression and reduces the virulence of P. aeruginosa. (A) exoY promoter
activity with 187R or DMSO. (B) exoT promoter activity with 187R or DMSO. (C) Western blot of the protein
levels of ExoS and ExoT with 187R and DMSO respectively. Statistical significance was determined using an
two-tailed student’s t-test (***, P<0.001).
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Figure 2.3 HeLa cell cytotoxicity assay. A) Cell lifting assay. Strain names: PAK: wild type PAK, pscJ-: PAK
ΔpscJ, No bacteria: No bacteria but only DMSO or 187R added into the HeLa cell culture. Statistical
significance was determined using an ANOVA test with Tukey-HSD analysis. Significant differences were
found between DMSO treated PAK infection group and all other groups (**, P<0.01). No significant differences
found among all other groups. B) HeLa cell morphology post infection with the present of DMSO (B), 187R
(C), and D) pscJ mutant
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Figure 2.4 vfr and exsA promoter activity. (A) exsA promoter activity in wild type with the presence of 187R
and DMSO respectively. exsA promoter activity of vfr mutant was served as control. (B) vfr promoter activity in
wild type with the presence of 187R and DMSO, respectively. vfr promoter activity of vfr mutant was served as
control.
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Figure 2.5 exsC promoter activity and amiE‘-’lacZ translational fusion expression (A) exsC promoter activity of
the wild-type P. aeruginosa in the presence of DMSO or187R. (B) exsC promoter activity in wild type and crc
mutant. (C) amiE‘-’lacZ expression level in the presence of DMSO or 187R, crc mutant was served as control.
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Figure 2.6 Expression ratio of rsmY and rsmZ mRNA level with the presence of DMSO and 187R. rpsL was
served as internal control. The fold change was log2 transformed (*, P<0.05).
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Figure 2.7 Effect of 187R on rsmY/Z/A regulatory pathway. (A) expression of tssA1‘-’lacZ translational fusion
reporter with 187R and DMSO respectively. (B) exoS promoter activity in in the rsmYZ double mutant with the
present of 187R and DMSO respectively. Statistical significance was determined using an two-tailed student’s ttest (**, P<0.01; ***, P<0.001).
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Expression ratio of rhlI in 187R/DMSO

Figure 2.8 Expression ratio of rhlI in 187R/DMSO. The ratio waslog2 transformed.
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Figure 2.9 Effect of 187R on c-di-GMP level. (A) cdrA promoter activity level with the presence of DMSO or
187R. cdrA promoter activity in ABTGC medium was used as a control. (B) Twitching and (C) swarming
motility of wild-type strain in the presence of DMSO or 187R.
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Figure 2.10 Effect of 187R on master regulator exsA. A) ExsA protein levels with DMSO and 187R
respectively. RNA polymerase (RNAP) was used as the loading control. B) qRT-PCR of exsA. Expression ratio
of exsA in 187R/DMSO. The ratio was log2 transformed. rpsL was served as internal control.
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Figure 2.11 deaD regulates T3SS expression and low temperature growth. A) exoS promoter activity
dramatically reduced in deaD mutant, adding 187R did not further reduced the exoS promoter activity. B) deaD
did not affect the growth of PAO1 at 37°C. The low temperature (16 °C) growth of deaD mutant was measured
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using an two-tailed student’s t-test (***, P<0.001).
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Figure 2.12 Translation of exsA with the presence of 187R or DMSO. (A) exsA‘-’lacZ and exsCEBA‘-’lacZ
translational fusion reporter construction. (B) exsA‘-’lacZ and (C) exsCEBA‘-’lacZ expression with the
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Figure 2.13 187R inhibits T3SS in the presence of SNP (NO donor). P. aeruginosa was cultured under T3SS
inducing condition. SNP was supplemented in the medium at the concentration of 3mM. Water was supplemented
as control. Statistical significance was determined using an two-tailed student’s t-test (**, P<0.01; ***, P<0.001).
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Table 2.1 Bacteria strains and plasmids used in this study.
Strain/plasmid

Description

Reference or source

PAO1

Wild-type strain

(109)

PAO1Δcrc

crc deletion mutant

(74)

PAO1ΔdeaD

deaD deletion mutant

This study

PAK

Wild-type strain

(26)

PAKΔpscJ

The pscJ mutant

(26)

PAKΔvfr-Pvfr

vfr

Pseudomonas aeruginosa

deletion

mutant

with

vfr-lacZ (35)

transcriptional fusion integrated into
chromosome
PAK-Pvfr

PAK

wild

type

with

vfr-lacZ (35)

transcriptional fusion integrated into
chromosome

E. coli
DH5α

F80dlacZ∆M15 ∆(lacZYA-argF) U169 (110)
recA1 hsdR17 deoR thi-1 supE44 gyrA96
relA1

Plasmids
pPROBE-AT

Cloning vector for transcriptional gfp (83)
fusions; Cbr

exoS-gfp

pPROBE-AT

containing

the

exoS (59)

containing

the

exoY This study

containing

the

exoT This study

containing

the

exsC This study

promoter; Cbr
exoY-gfp

pPROBE-AT
promoter; Cbr

exoT-gfp

pPROBE-AT
promoter; Cbr

exsC-gfp

pPROBE-AT
promoter; Cbr
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exsA-gfp

pPROBE-AT

containing

the

exsA This study

promoter; Cbr
pME6013

Cloning vector for translational lacZ (111)
fusions; Tcr

pME9655

pME6013 with amiE'-'lacZ; Tcr

pSW205

lacZ translational fusion vector carrying (84)

(74)

the P. aeruginosa 1.8 kb stability
fragment; Cbr
exsA ‘-’ lacZ

pSW205 carry exsA transcriptional start This study
site to +52 codon of exsA, driven by
LacUV5 promoter

exsCEBA ‘-’ lacZ

pSW205 carry exsC transcriptional start This study
site to 52 codons of exsA, driven by
LacUV5 promoter

tssA1 ‘-’ lacZ

pSW205 carry +1 to +188 of tssA1, This study
driven by LacUV5 promoter

pEX18GM

P. aeruginosa gene replacement vector; (112)
sacB, Gmr

pEX18GM-deaD

pEX18GM carrying deaD deletion allele This study
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Table 2.2 Oligonucleotide primers utilized in this study,
underlines indicates restriction enzyme sites
Primer

Sequence (5′→3′)

exoY-gfp
PexoY-F

ATGGATCCGACGGTACGTACTTCGCGAC

PexoY-R

ATGAATTCTGCATATCCGCAGGGCGCAG

exoT-gfp
PexoT-F

TAGGATCCCACCAAGAGCCCGTCGCTGC

PexoT-R

ATGAATTCCCAGGCGCCCGGCCACGGC

exsC-gfp
PexsC-F

ATTGTCGACGCAGAAGGTCGAGGACCAGATG

PexsC-R

ATTGAATTCGATACGGCCTGCGAACTCGGC

exsA-gfp
PexsA-F

ATTGTCGACTACATTGCCTGCTGTTTCGG

PexsA-R

ATTGAATTCGGCCAAGAGATTTGGCTCC

cdrA-gfp
PcdrA-F

ATTGTCGACGCAGTTGCAGCTCGTCGAA

PcdrA-R

ATTGAATTCCGGACGGACCATGAAAATCT

exsA ‘-’ lacZ translational fusion
Post exsA -F

AAAGAATTCAGGCTTTACACTTTATGCTTCCGGCTCGTAT
AATGTGTGG CGTGCTCATGGCTTTGAAAATC

Post exsA -R

AAAGGATCC CGCCAGGCAAAAAGTGGAAT

tssA1 ‘-’ lacZ translational fusion
Post tssA1 F

AAAGAATTCAGGCTTTACACTTTATGCTTCCGGCTCGTAT
AATGTGTGGAACCTTTCGAGTCATCCAATAT
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Post tssA1 R

AAGGATCCGCGTCGTACTCCAGATCG

deaD deletion mutant
deaD Upstream-F

AAA AAGCTTCGAGACGATAGGCTTCGTGG

deaD Upstream-R

GGACCTCAGTCCTCGCGAGTCATGGGTTTGCCTCGTAT

deaD downstream-F

ATACGAGGCAAACCCATGACTCGCGAGGACTGAGGTCC

deaD downstream-R

AAAGGATCC ACGACTTCTACGGCTTTCCG

qRT-PCR primer
rpsL - F

TGAAGGTCACAACCTGCAAGAGCA

rpsL - R

AACGACCCTGCTTACGGTCTTTGA

exsA - F

CAAGGGAAAGGACAGCCGAA

exsA - R

ACGCTCGACTTCACTCAACA

rsmY-F

TCAGGACATTGCGCAGGAA

rsmY-R

TTTGCAGACCTCTATCCTGACATC

rsmZ-F

GGAACACGCAACCCCGAAGG

rsmZ-R

CCGCCCACTCTTCAGTCCCT

rhlI-F

ATCCGCAAACCCGCTACATC

rhlI-R

TAGGCGAAGACGTCCTTGAG
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Table 2.3 Ciprofloxacin susceptibility of P. aeruginosa PAO1 grow with DMSO or 187R

a

Condition

DMSO

187R

MICa

1-2mg/L

1-2mg/L

MIC of ciprofloxacin was measured with DMSO or 187R (250 µM) supplemented in the growth medium. MIC

was determined by the minimal concentration of ciprofloxacin without growth.
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Chapter 3 : Anti-virulence compound
preserve the microbial community better
than the traditional antibiotics
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Abstract
Antibiotic therapies are known to disrupt the microbiota and have long-term negative
influence on the hosts’ health status. Anti-virulence compounds target the virulence factors but
do not affect cell components that are essential for cell survival. Therefore, anti-virulence
therapies are considered as alternative antimicrobial therapies that can better preserve the hostassociated microbial community. Although several studies evaluating the efficacy of antivirulence compounds on infectious diseases have been conducted, the impact of anti-virulence
compounds on host microbial community has been seldom investigated. In this study, we used
16S Illumumia sequencing to test the impact of the anti-virulence compound, designated as
187R, on the composition of a P. aeruginosa hosts microbial community (Arabidopsis
phyllosphere) in comparison to the treatment of streptomycin. Although the culture
independent sequencing method is a powerful tool for studying the microbial community, it
cannot assess the bioactivity and viability of the microbial community. To address this
limitation, we also used the Biolog EcoPlate assay to compare the viability and metabolic
function of the 187R-and streptomycin-treated microbial community. After examining the
Illumina sequencing results and the carbon profile of 187R-, DMSO- and streptomycin-treated
phyllosphere. We found that microbial community composition and metabolic function of the
187R-treated phyllosphere were more similar to the DMSO-treated phyllosphere (negative
control) than the streptomycin-treated group. The results suggest that anti-virulence
compounds can preserve the microbial community better than antibiotics.

Introduction
Microorganisms inhabit almost every imaginable environment in the biosphere. These
microbes play crucial roles in the ecosystems all around the world for cycling elements such
as carbon, oxygen, nitrogen and metal (113). For example, the soil microbial community is
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essential for decomposing the organic matters in forest soil, further influencing the carbon
cycle and nutrient composition in the soil (114). In addition, in many ecosystems such as the
tropical forest ecology system, the microbial community is considered as a key factor for
maintaining the bio-diversity through negative feedback mechanisms (i.e., accumulation of
pathogens inhibits the growth of plant seedlings) (115). The microbial communities in different
areas, or symbiotic microbes in different hosts, feature their unique compositions and
diversities (116). These microbial communities also have special functions affecting the hosts’
health status. For example, the gut microbial community provides nutrients to the host,
represses pathogens and parasites, and stimulates the development of the host’s immune system
(63, 64). Studies have suggested that phyllosphere microbial communities (i.e., microbial
community on the leaf surface) limit the number of invasive pathogenic bacteria on the leaf
surface via competition, as a result alleviating diseases (117).
Antibiotic therapy has been widely applied for treating the bacterial and fungal infections in
human and animals since Alexander Fleming discovered penicillin in 1928. However, the
current antibiotic therapy targets the cellular components which are essential for cell survival.
The strong selective pressure leads to the development of antibiotic resistance and causes the
accumulation of antibiotic resistant genes in the host gut microbiota. As a result, the hostassociated microbiota becomes a potential pool of resistant genes and poses public health risk
(118). Moreover, the cellular components serving as the targets of antibiotics, especially the
broad-spectrum antibiotics, are conserved in many different bacteria species including both
pathogenic and nonpathogenic microbes. Therefore, the antibiotic treatment also affects the
nonpathogenic microbes and disturbs the hosts’ microbial communities (58, 119). The
disruption of hosts’ microbes sometimes causes severe diseases. For example, gut microbial
disorder correlates with Clostridium difficile infection (68) and inflammatory bowel disease
(69). The recovery of microbiota after treatment with antibiotics can take up to years (70),
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which could potentially shorten the life span of the host (58, 120).
The anti-virulence therapies target the virulence factors instead of the essential components
for cell survival. Therefore, it has been expected that the anti-virulence therapies can minimize
the damage to the hosts’ microbiota (72). However, few studies have been done to prove the
theory. This study aimed to evaluate the anti-virulence compound impacts on host (i.e.,
Arabidopsis phyllosphere) from the perspective of the microbial community. Three treatments,
including the virulence compound (i.e., 187R), control group (i.e., DMSO) and antibiotics (i.e.,
streptomycin) were applied to observe the corresponding impacts on phyllosphere microbes.
Our results showed that 187R treatment group had more similar Arabidopsis phyllosphere to
the control group compared with streptomycin, indicating less disturbance to host microbiota
from this anti-virulence compound. This observation suggests such alternate antimicrobial
therapy may be able to preserve non-pathogen host microbiota, causing less negative impacts
on the host health condition compared to the widely-applied antibiotics.
Anti-virulence compound is considered as narrow-spectrum or even species-specific since
the regulatory of virulence factors such as T3SS are very different in different pathogens. In
our study, we also tested the spectrum of our anti-virulence compound 187R by testing the
impact of 187R on a Hrp (Hypersensitive responses and pathogenicity) T3SS. Hrp T3SS is
conserved among plant pathogens such as D. dadantii, E. amylovora and Psedomonas syringae
(121). The Hrp T3SS in these three bacteria is activated by alternative sigma factor HrpL. In
our experiment, we tested if the expression of D. dadantii and E. amylovora hrpA gene, which
encodes a major component of T3SS pilus, altered by 187R (122, 123). We found that the hrpA
expression has not changed in both D. dadantii and E. amylovora. These results showed that
187R is not a broad-spectrum anti-virulence compound.
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Materials and Methods

Phyllosphere collection
For testing the effect of 187R on the phyllosphere, eight weeks Arabidopsis thaliana Col-1
were moved from the pot to 2mL microcentrifuge tubes with the root immersed in water. The
leaves were sprayed twice (8 hours between each spray) with 187R (35 µM), DMSO (negative
control) or streptomycin (200 ppm), respectively. DMSO was also added into the streptomycin
solution before spraying. The leaves were collected after the plants were kept at room
temperature for overnight. The collected leaves were gently washed in PBS for cleaning the
remaining compound and antibiotics. The washed leaves were placed in sterile tubes containing
30 mL PBS. The phyllosphere were collected by sonicating the test tubes in a water bath
sonicator for 15 minutes. Samples were collected in triplicate for each treatment. A total of 2224 plants were used in each treatment.

16S rRNA gene illumina sequencing and data analysis
PBS containing phyllosphere microbes collected from above were centrifuged and the cell
pellets were used for microbial DNA extraction with the Qiagen Dneasy Powersoil kit (Qiagen,
Germany) following manufacturer’s instructions. The quantities of the genomic DNA were
measured by Nanodrop spectrophotometer. Approximately 10ng of DNA were added into the
PCR reaction as template. The V4 region of 16s rRNA gene was amplified using the 16S_515F
and 16S_806R primers with Illumina sequencing adaptors (16S_515F: TCG TCG GCA GCG
TCA GAT GTG TAT AAG AGA CAG GTG CCA GCM GCC GCG GTA A; 16S_806R: GTC
TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA GGG ACT ACH VGG GTW TCT
AAT) (124). PCR amplification consisted of 95°C for 45 s, followed by 38 cycles of 95°C for
15 s, 78°C for 10 s, 60°C for 30 s, and 72°C for 30 s (125). PNA (peptide nucleic acid) clamps
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mPNA and pPNA clamps (mPNA: GGC AAG TGT TCT TCG GA and pPNA: GGC TCA
ACC CTG GAC AG) (126, 127), which binds to and blocks the amplification of mitochondria
and chloroplast DNA, respectively, were added to the PCR reaction at a final concentration of
0.75 µM. The PCR products was purified by QIAquick Gel Extraction Kit (QIAGEN).
Microbial community Illumina sequencing data was analyzed by Qiime version 1.9.1 (128).
Open-reference OTU (Operational Taxonomy Unit) picking method using GreenGenes
reference database version 13.8 (129) was performed for OTU clustering and taxonomy
assignments. Principle coordinates analysis (PcoA) of microbial communities was performed
based on the Unifrac distance matrix (130).

Testing the impact of 187R on phyllosphere with culture dependent Biolog EcoPlate.
The different members of a microbial community have different growth requirements and
utilize different carbon sources, therefore, the microbial community can decompose different
organic carbon and involved in the nutrient cycling. Alternating the microbial community may
change its carbon utilization. In this assay, the ability of the phyllosphere microbial
communities treated by 187R, DMSO or streptomycin, utilizing the carbon sources were
assessed by BioLog EcoPlate. Each EcoPlate has 96 wells containing 31 carbon sources and
one blank control in three replicas. Tetrazolium violet redox dye was used to evaluate the
substrate (carbon source) metabolization. For the EcoPlate assay, 2mL of PBS containing the
suspended phyllosphere was diluted 1:20 (vol:vol) in sterile PBS. PBS contains diluted
phyllosphere suspension was aliquoted into each well (120µL) of the Biolog EcoPlate. The
carbon utilization was determined by Telcon plate reader using OD590nm after 48 hours
incubation. The results were analyzed by Principle Component Analysis (PCA) using R (90)
package FactoMineR (131). The heatmap with clustering analysis was generated based on
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average OD590 value of each carbon source within each treatment using R package gplots
(132).

Testing the expression of T3SS in Erwinia amylovora and Dickeya dadantii
Erwinia amylovora 273 and Dickeya dadantii 3937 are plant pathogens processing T3SS.
We tested the T3SS gene expression by measuring the T3SS regulon gene hrpA expression in
these two strains. E.amylovora 273 and D. didantii 3937 carrying a phrpA reporter plasmid
were used in this assay. The reporter plasmid phrpA for E. amylovora 273 was constructed by
cloning E. amylovora hrpA promoter region into pPROBE-NT (123). The reporter plasmid
phrpA for D. dadantii 3937 was constructed by cloning D. dadantii 3937 hrpA promoter region
into pPROBE-AT (133). The strains carrying phrpA reporter plasmid at 1:1000 were
inoculated into Minimal Medium (133) with 250 µM of 187R. E. amylovora or D. didantii
3937 harboring the T3SS hrpA -gfp transcriptional fusion reporter treated with DMSO (solvent
for screening compound) were used as negative control. Bacteria were cultured overnight at
28°C before harvesting. The harvested bacterial cells were 1:10 diluted in PBS and the GFP
intensity was measured using fluorescence-activated cell sorter flow cytometry (FACS) (BD
Biosciences, CA).

Results

Comparison of the impact of 187R and streptomycin on phyllosphere microbe
compositions
There were a total of 19 phyla were observed for each treatment group, with Proteobacteria
and Bacteroidetes as the two most abundant phyla. In the control group, Proteobacteria and
Bacteroidetes composed on average 67% and 25% of the whole community, respectively.
Phylum Verrucomicrobia and phylum Firmicutes each occupied about 1% of the whole
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community (Fig. 3.1). Compare to the control group, the 187R-treated group, in which
Proteobacteria and Bacteroidetes composed on average 62% and 30% of the whole community,
showed similar relative abundances of different phyla (Fig. 3.1 & Fig. 3.2). Compared to the
DMSO treated group, the antibiotic treated-group showed reduced relative abundance of
Proteobacteria and increased relative abundance of Bacteroidetes and Verrucomicrobia. In
particular, the average abundance of Proteobacteria reduced to 37%; Bacteroidetes and
Verrucomicrobia increased to 51% and 6%, respectively (Fig. 3.1 & Fig. 3.2).
To further evaluate similarities of the microbial communities of different treatments,
principle coordinates analysis (PcoA) was performed based on the Unifrac distance of different
phyllosphere samples (Fig. 3.3). The antibiotic-treated phyllosphere was well separated from
the 187R- and DMSO-treated phyllosphere along PC1, indicating antibiotic altered
phyllosphere to a larger extent compared to 187R. Unifrac monte carlo significance test were
conducted checking the phylogenetical differences between each pair of samples in our
experiment. The test confirmed that all the streptomycin-treated phyllosphere are significantly
different from the DMSO-treated phyllosphere (p < 0.05); however, no significant difference
was observed when compared 187R-and DMSO-treated phylospheres. Overall, these results
suggested that anti-virulence compound 187R preserved the microbial community composition
better than the antibiotics.

187R preserved the metabolic functions of the phyllosphere better than antibiotics.
The change of microbial metabolic function such as carbon metabolism may reflect the
viability and metabolism of the microbial community. In order to test whether compositions of
phyllosphere in 187R and antibiotics treatment groups can comprehensively represent the
corresponding functional profiles, we used the EcoPlate assay to test the carbon metabolism
(an important function related to microbe survival and nutrient cycling) of 187R-, DMSO- or
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streptomycin-treated phyllosphere. The heatmap with clustering analysis was generated based
on average OD590 of each carbon source within each treatment. The results demonstrated that
187R-and DMSO-treated phyllospheres shared similar pattern in terms of carbon metabolism
profile (Fig. 3.4). However, the carbon metabolism profile of streptomycin-treated
phyllosphere was different from the DMSO-and 187R-treated phyllospheres. Besides 2Hydroxy Benzoic Acid and L-Threonine, which cannot be used by phyllosphere microbes as
carbon sources, 13 out of 29 carbon sources showed more than two-fold reduction of OD590
(carbon metabolism) compared to those in the DMSO-treated phyllospheres. Moreover, the
antibiotic-treated phyllospheres even lost the ability of using phenylethylamine as carbon
source (indicated by arrow in Fig. 3.4). However, 187R-treated phyllosphere, has not shown
such dramatic change in terms of carbon utilization (Fig. 3.4). The PCA analysis for carbon
profiles of all 12 samples suggested that the carbon profiles of all three streptomycin-treated
phyllospheres were greatly differed from the carbon profiles of DMSO-treated (control)
phyllosphere. The samples were well separated along dimension 1 (Dim1), which explained
49.69% of the variation. Compared to carbon profiles of streptomycin-treated phyllosphere,
the carbon profiles of three 187R-treated phyllospheres showed higher similarity to the carbon
profiles of DMSO-treated (control) phyllospheres (Fig. 3.5). The results confirmed that there
were drastic changes in antibiotic-treated phyllospheres but not in 187R-treated phyllospheres.
Moreover, the results also suggested that compared to the antibiotic streptomycin, antivirulence compound 187R showed less impact on the microbial community carbon metabolism.

187R does not inhibits the T3SS of two other bacterial pathogens.
To test the specificity of 187R on other Gram negative bacteria possessing T3SS, we treated
the E. amylovora and D. dadantii 3937 with 187R under T3SS inducing conditions. The
expression of hrpA gene, which encodes the major subunit of the Hrp pilus, is under the
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regulation of sigma factor HrpL (123, 133). We found that the expression of hrpA was not
affected by adding 187R (Fig. 3.6), indicating that the anti-virulence compound 187R may be
specific to the T3SS of P. aeruginosa.

Discussion
We found that by targeting the virulence factors of pathogens can reduce their ability to
cause infections while preserving the host-associated microbiota. In this research, cultureindependent and culture-dependent method were applied for testing the impact of an antivirulence compound on P. aeruginosa host microbial community (Arabidopsis phyllosphere).
Our results suggested that compared to antibiotics, 187R, and likely other anti-virulence
compounds preserved the microbial community in terms of composition and function better
than the traditional antibiotics. In addition, our anti-virulence compound did not affect the
T3SS of E. amylovora and D. dadantii 3937, which indicates 187R-mediated T3SS inhibition
is specific to P. aeruginosa.
In this experiment, we observed that the addition of PNAs greatly reduced the amplification
of hosts’ DNA including the mitochondria and chloroplast DNA (125). In our sequencing
dataset, two sequences of chloroplast were found and no mitochondria sequences were
observed, suggesting that supplementation of PNAs decreased the bias of microbial community
analysis caused by host DNA amplification.
The EcoPlate assay highlighted the effect of anti-virulence compound on preserving the
microbial community composition and metabolic functions, suggesting that the anti-virulence
compound greatly reduced the damage of hosts’ microbial community compared to the
traditional antibiotics. A major limitation of the using culture-independent method examining
the microbial community is that it cannot differentiate the viable and dead microbes in the
ecosystem; therefore, the effects of treatments on the phyllosphere may be underestimated
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(134). In addition, microbial communities are not only characterized by their species
composition, they are also featured with different functional genes (for example, genes related
to carbon and nitrogen metabolism) that are responsible for the microbes’ bioactivities such as
nutrient cycling and immunomodulation (135, 136). It has always been discussed that changing
the microbial community composition would not necessarily result in the alternation of
microbial community function due to its high functional redundancy (137, 138). Therefore, it
is questionable that whether alternating the species composition would affect the hosts and
ecosystems. Our culture-dependent EcoPlate method addressed these limitations of how
antibiotics and anti-virulence compounds affect the viability and metabolic functions microbial
communities. In this study, the EcoPlate assay testing the carbon metabolism profile of
microbial communities showed that while 187R-treated samples showed similar carbon
utilization profile to the DMSO control, the antibiotic-treated phyllosphere showed reduced
capability of carbon utilization.
While checking the carbon metabolism profile of different phyllosphere, we observed that
the carbon utilization profile was greatly altered in the microbial community treated with
antibiotics. (Fig 3.4 & 5). Besides the altered composition of bacteria in the antibiotic-treated
samples, the inhibitory mechanism of streptomycin may also contribute to the altered carbon
metabolism. Streptomycin is a bacteriostatic agent. The research conducted in Gram negative
bacteria E. coli showed that streptomycin interferes with protein synthesis by disturbing the
stability of mRNA-ribosomal complex and inducing misreading of genetic code (139). As a
result, although the bacteria may still survive in the community, the accumulation of mutated
protein hampered their bioactivity and caused a decreased carbon metabolic rate. Further
research for elucidating the impact of bacteriostatic agents, such as streptomycin, on the
metabolic functions need to be done.
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By testing the T3SS of E. amylovora and D. dadantii 3937, we found that 187R does not
inhibit the hrp T3SS of these two bacteria, thus indicating that 187R may be a narrow-spectrum
T3SS inhibitor specific for P. aeruginosa. The narrow-spectrum of 187R may also contributed
to the preservation of the host microbial community since T3SS may also involve in shaping
the bacterial habitat via interacting with the fungi and change its morphology (121).
In conclusion, using high-throughput sequencing and culture dependent EcoPlate assay,
we studied the impact of anti-virulence compound on host microbial communities and the hostassociated microbial community composition and metabolic function better than the traditional
antibiotics. This discovery may allow us to target virulence factors of the pathogen while not
altering the host microbiota. Our study indicates that anti-virulence compounds are good
alternative strategy for new antimicrobial therapy development.
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Figure 3.1 Average relative abundance of microbial communities at phylum level. Legend listed on the right
side of the figure. 187R, phyllosphere treated by T3SS inhibitor 187R; DMSO, phyllosphere treated by DMSO;
Streptomycin, phyllosphere treated by antibiotic streptomycin. Each pie graph demonstrates the mean
abundance of three individual samples.
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Figure 3.2 Relative abundance of microbial communities at phylum level. Legend listed on the right side of the
figure. 187R, phyllosphere treated by T3SS inhibitor 187R; DMSO, phyllosphere treated by DMSO;
Streptomycin, phyllosphere treated by antibiotic streptomycin.
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Figure 3.3 Principal Coordinate Analysis (PcoA) of microbial communities based on weighted Unifrac distance.
Legend listed on the right side of the figure. 187R, phyllosphere treated by T3SS inhibitor 187R; DMSO,
phyllosphere treated by DMSO; Streptomycin, phyllosphere treated by antibiotic streptomycin.
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Figure 3.4 Heatmap with cluster analysis of carbon metabolism profile. Color key indicates the OD590 value
listed on the left side of the figure. Carbon source listed on the right side of the figure. 187R, phyllosphere treated
by T3SS inhibitor 187R; DMSO, phyllosphere treated by DMSO; Streptomycin, phyllosphere treated by antibiotic
streptomycin. Arrow indicated the phenylethylamine, the carbon source cannot be utilized by streptomycin treated
phyllosphere.
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Figure 3.5 Principal Component Analysis (PCA) of microbial communities carbon metabolism profile. Legend
listed on the inside of the figure. 187R, phyllosphere treated by T3SS inhibitor 187R; DMSO, phyllosphere
treated by DMSO; Streptomycin, phyllosphere treated by antibiotic streptomycin. The percentage under the axis
indicate the variation the axis explained.
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